ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1848

Human Gingiva-Derived Mesenchymal Stromal Cells Inhibit Graft-Versus-Host Disease Through CD39 and IDO

Song Guo Zheng1, Maogeng Chen1, Dong Dong Chen2, Jian Gu3 and Yi Shen4, 1Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, 2Medicine, Zhoushan Hospital at Zhejiang Province, Zhoushan, China, 3Medcine, University of Southern California Keck School of Medicine, Los Angeles, CA, 4Medicine, Shanghai East Hospital at Tongji University, Shanghai, China

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, Rheumatic disease, stem cells and therapy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: We recently have reported that human-derived gingival mesenchymal stem cells (GMSC) have strong capacity to suppress immune responses and T cell-mediated collagen-induced arthritis, however, it is unclear whether these cells can suppress human T cell-mediated diseases. In this project, we have developed a humanized animal model to investigate the interventional role of human GMSC in xeno-GVHD model, which is a best animal model to study human cell therapy prior to clinical trial.

Methods: Human gingival tissues were gained from discard samples from the patients who underwent dental operation. GMSC were isolated and grown from gingival tissues and cultured in α-MEM with 10%FBS for 3-6 generations. GMSC were harvested and added to human CD25 depleted CD3+ T cells for the co-culture with 0.025ng/ml anti-human CD3 antibody for in vitro suppression test. To determine the relative molecular mechanisms, various inhibitors and antagonists were added to the cultures. In vivo, sub-lethally irradiated NOD mice were given 2 × 107 peripheral blood mononuclear cell (PBMC) intravenously (IV) without (PBMC group) or with 2 × 106 GMSC (PBMC + GMSC group), while other NOD mice received 2 × 106 nTreg (PBMC + nTreg group) or 2×106 human fibroblast cell (PBMC + Fibroblast) for the controls. The levels of cytokines and IgG in mouse serum were measured by ELISA. Mice weight was measured twice a week and survival was monitored.

Results:  We showed that GMSCs potently suppress the proliferation of human PBMC in vitro independent of cell contact. GMSC also suppress Th1, Th2 and Th17 cell differentiation. Co-transfer of human PBMC and GMSC significantly suppress IFN and IgG production, maintained weight and prolonged the mouse survival. In contrast, the adoptive transfer of human fibroblast cells did not suppress xeno-GVHD. Moreover, we demonstrated that GMSCs suppress xenogenic response of human PBMCs via CD39 and IDO signals.

Conclusion: Human GMSCs can suppress human immune responses and immune system-mediated diseases, offering a pre-clinical option to be used for modulating GVHD and other autoimmune diseases.


Disclosure:

S. G. Zheng,
None;

M. Chen,
None;

D. D. Chen,
None;

J. Gu,
None;

Y. Shen,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/human-gingiva-derived-mesenchymal-stromal-cells-inhibit-graft-versus-host-disease-through-cd39-and-ido/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology